Lannett Company, Inc. announced this week that they have received approval from the Food & Drug Administration to manufacture generic Buprenorphine and Naloxone sublingual tablets. Available dosages will come in 2mg and 8mg tabs similar to the equivalent dosages available with Suboxone.
Lannett specialize in generic pharmaceuticals for a wide range of medical purposes. Arthur Bedrosian, Lannett’s CEO, was quoted as saying that “Buprenorphine and Naloxone Sublingual Tablets, a Class III drug, is an important medication for the treatment of opioid addiction”.
The increased affordability of a generic Buprenorphine option coupled with higher patient limits for buprenorphine-approved physicians should open the door for addicted individuals to receive improved access to important addiction treatment services.
Buprenorphine is currently available by prescription in every metropolitan area throughout the United States as well as most smaller towns and cities.